Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells

Journal of Ethnopharmacology

Volumn 106, Issue 1, 2006, Pages 121-128

  Rhule, Ava ^a   Navarro, Severine ^b   Smith, Jerry R ^a   Shepherd, David M ^a,b  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Ginsenosides; Inflammation; Macrophages; Panax notoginseng; RAW264.7

Indexed keywords

CD14 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 2; GINSENOSIDE RB 1; GINSENOSIDE RG 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PANAX NOTOGINSENG EXTRACT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SAMPLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2; CYTOKINES; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; PANAX; PLANT EXTRACTS; RNA, MESSENGER;

ANIMALIA; PANAX NOTOGINSENG;

EID: 33646534388     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2005.12.012     Document Type: Article

References (42)

1. Abreu M.T., and Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. The Journal of Pediatrics 144 (2004) 421-429
2. Akashi S., Shimazu R., Ogata H., Nagai Y., Takeda K., Kimoto M., and Miyake K. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. The Journal of Immunology 164 (2000) 3471-3475
3. Andreakos E., Foxwell B., and Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunological Reviews 202 (2004) 250-265
4. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology. Multiple constituents and multiple actions. Biochemical Pharmacology 58 (1999) 1685-1693
5. Barnes, P., Powell-Griner, E., McFann, K., Nahin, R., 2004. Complementary and Alternative Medicine Use Among Adults: United States, 2002. Advanced Data From Vital Health Statistics, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, p. 343.
6. Beutler B. Innate immune response to microbial poisons: discovery and function of the toll-like receptors. Annual Review of Pharmacology and Toxicology 43 (2003) 609-628
7. Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. General Pharmacology: The Vascular System 29 (1997) 127-150
8. Chuang W.C., Wu H.K., Sheu J.S., Chiou S.H., Chang H.C., and Chen P.Y. A comparative study on commercial samples of ginseng radix. Planta Medica 61 (1995) 459-465
9. Dayer J.M. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Practice and Research Clinical Rheumatology 18 (2004) 31-45
10. Diehl S., and Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Molecular Immunology 39 (2002) 531-536
11. Dunzendorfer S., Lee H.K., Soldau K., and Tobias P.S. TLR4 is the signaling but not the lipopolyssacharide uptake receptor. The Journal of Immunology 173 (2004) 1166-1170
12. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annual Review of Immunology 16 (1998) 111-135
13. Hanada T., and Yoshimura A. Regulation of cytokine signaling and Inflammation. Cytokine and Growth Factor Reviews 13 (2002) 413-421
14. He N., and Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. American Journal of Therapeutics 11 (2004) 206-212
15. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitation: the control of NF-kappaB activity. Annual Review of Immunology 18 (2000) 621-663
16. Keum Y.S., Han S.S., Chun K.S., Park K.K., Park J.H., Lee S.K., and Surh Y.J. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression. NF-kappaB activation and tumor promotion. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 523/524 (2003) 75-85
17. Klepser T.B., and Klepser M.E. Unsafe and potentially safe herbal therapies. American Journal of Health-System Pharmacy 56 (1999) 125-138
18. Kwan C. Vascular Effects of selected Antihypertensive drugs derived from traditional medicinal herbs. Clinical Experimental Physiology 22 (1995) S297-S299
19. Lee S.K., Surh Y.J., Choi K.J., and Ko S.R. Effects of selected ginsenosides on phorbol ester-induced expression of cyclooxygenase-2 and activation of NF-kappaB and ERK1/2 in mouse skin. Annals of the New York Academy of Sciences 973 (2002) 396-401
20. Lefkowitz D.L., Mills K., Lefkowitz S.S., Bollen A., and Moguievsky N. Neutrophil-macrophage interaction: a paradigm for chronic inflammation. Medical Hypotheses 44 (1995) 58-62
21. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annual Review of Immunology 14 (1996) 233-258
22. Li L., Zhang J.L., Sheng Y.X., Guo D.A., Wang Q., and Guo H.Z. Simultaneous quantification of six major active saponins of Panax notoginseng by high-performance liquid chromatography-UV method. Journal of Pharmaceutical and Biomedical Analysis 38 (2005) 45-51
23. Li S.H., and Chu Y. Anti-inflammatory effects of total saponins of Panax notoginseng. Zhongguo Yao Li Xue Bao 20 (1999) 551-554
24. Li X., and Stark G.R. NFkappaB-dependent signaling pathways. Experimental Hematology 30 (2002) 285-296
25. Luscinskas F.W., and Gimbrone M.A. Endothelial-dependent mechanisms in chronic inflammation leukocyte recruitment. Annual Review of Medicine 47 (1996) 413-421
26. Mullenheim J., Frassdorf J., Preckel B., Thamer V., and Schlack W. Ketamine, but not S(+)-ketamine, blocks ischemic preconditioning in rabbit hearts in vivo. Anesthesiology 94 (2001) 630-636
27. Oh G.S., Pae H.O., Choi B.M., Seo E.A., Kim D.H., Shin M.K., Kim J.D., Kim J.B., and Chung H.T. 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Letters 205 (2004) 23-29
28. Park E.K., Choo M.K., Joo Han M., and Kim D.H. Ginsenoside Rh 1 possesses antiallergic and anti-inflammatory activities. International Archives of Allergic Immunology 133 (2004) 113-120
29. Quezida S.A., Jarvin L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the Interface of tolerance and immunity. Annual Review of Immunology 22 (2004) 307-328
30. Rice T.W., and Bernard G.R. Therapeutic intervention and targets for sepsis. Annual Review of Medicine 56 (2005) 225-248
31. Rocca B., and FitzGerald G.A. Cyclooxygenases and prostaglandins: shaping up the immune response. International Immunopharmacology 2 (2002) 603-630
32. Sengupta S., Toh S., Sellers L., Skepper J., Koolwiijk P., Leung H., Yeung H., Wong R., Sasisekharan R., and Fan T. Modulating angiogenesis: the yin and yang in Ginseng. Circulation 110 (2004) 1219-1225
33. Shepherd D.M., Steppan L.B., Hedstrom O.R., and Kerkvliet N.I. Anti-CD40 treatment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-exposed C57Bl/6 mice induces activation of antigen presenting cells yet fails to overcome TCDD-induced suppression of allograft immunity. Toxicology and Applied Pharmacology 170 (2001) 10-22
34. Smith J.R., Thiaagraraj H.V., Seaver B., and Parker K.K. Differential activity of lipoic acid enantiomers in cell culture. Journal of Herbal Pharmacotherapy (2005) 5
35. Smolinski A.T., and Pestka J.J. Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb(1) (ginseng) and parthenolide (feverfew). Food and Chemical Toxicology 41 (2003) 1381-1390
36. Stylianou E., and Saklatvala J. Interleukin-1. The International Journal of Biochemistry and Cell Biology 30 (1998) 1075-1079
37. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annual Review of Medicine 53 (2002) 35-57
38. Watowhich S.S. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annual Review of Cell and Developmental Biology 12 (1996) 91-128
39. Xu Q.F., Fang X.L., and Chen D.F. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. Journal of Ethnopharmacology 84 (2003) 187-192
40. Yun T.K. Brief introduction of Panax ginseng C.A. Meyer. Journal of Korean Medical Science 16 (2001) S3-S5
41. Zhang W.J., Wojta J., and Binder B.R. Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Arteriosclerosis, Thrombosis and Vascular Biology 17 (1997) 465-474
42. Zhu S., Zou K., Fushimi H., Cai S., and Komatsu K. Comparative study on triterpene saponins of Ginseng drugs. Planta Medica 70 (2004) 666-677